174 results about "Inositol" patented technology

The invention belongs to the field of skin care products, and particularly relates to an anti-wrinkle and anti-aging composition as well as a preparation method and application thereof, and the anti-wrinkle and anti-aging composition comprises neurotransmitter inhibition peptide, signal peptide, madecassoside, inositol and glycosylglycerol. The neurotransmitter inhibition type peptide is at least three of acetyl hexapeptide-8, arginine / lysine polypeptide, dipeptide diaminobutyrylbenzylamide diacetate and acetyl octapeptide-3, and the signal type peptide is at least two of palmitoyl pentapeptide-4, decapeptide-4 and acetyl tetrapeptide-9. Compared with the prior art, all the components of the anti-wrinkle and anti-aging composition act on different anti-aging pathways and can be matched with one another from multiple aspects of oxidation resistance, inflammation resistance, moisturizing, cell viability enhancement, wrinkle reduction and the like, a more comprehensive and better anti-aging effect is provided, skin aging is comprehensively resisted, the skin is in a more young state, and the anti-wrinkle and anti-aging composition has the advantages that the anti-wrinkle and anti-aging effects are achieved. And the anti-wrinkle and anti-aging composition is small in irritation and good in stability.

The present application relates to the field of cosmetic technology, in particular to a composition for improving skin firmness, a cosmetic and a preparation method thereof.The composition for improving skin firmness comprises the following components by weight: 0.1-10 parts of golden microalgae, 0.1-20 parts of rice fermentation liquor and 0.01-3 parts of inositol; wherein the fermentation strain of the rice fermentation liquor is yeast.The composition for improving skin firmness is mild and non-irritating, has strong permeability, can be used in cosmetics, enhances the generation of skin collagen and elastic fibers, and effectively improves skin firmness and elasticity.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and / or a Glycogen synthase kinase 3β (GSK3β) inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength in combination with either an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor and / or a composition or compound that increases cyclin D1. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength; and exposing the cancer cell to a PI3K inhibitor.

Provided herein are compositions comprising a silicate, inositol, and optionally an amino acid, which have improved solubility and / or are crystalline. Also provided are methods of making the disclosed compositions, as well as methods of making beverages comprising the disclosed compositions.

The invention relates to the technical field of grease processing, and discloses a method for increasing the sn-2 DHA content in schizochytrium limacinum triglyceride. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is more than 120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to the sn-2 site of triglyceride is remarkably promoted, so that the yield and content of sn-2 DHA are improved.

The application relates to the technical field of powder material packaging equipment, and discloses an inositol pipeline sterile environment packaging device, which comprises a sterile pipeline, a fixing frame, a conveying mechanism, a discharging assembly, a sealing mechanism and a packaging assembly, the fixing frame is installed in the sterile pipeline, and various functional assemblies are sequentially arranged along the conveying mechanism. A spherical material carrier is matched with an arc-shaped spherical discharger, precise quantitative discharging and residual cleaning are realized through the combination of a limiting ring and collision vibration, the ring-shaped cutting tool is integrally designed with the flat limiting ring to improve the sealing property of the seal, spring buffer clamping, gear and tooth ring transmission realize stable screwing of the bottle cap, and the conveying mechanism linkage multi-station realizes process synchronization. Through structural innovation and process integration, the device considers the sterile property, precision, sealing property and high efficiency, effectively avoids pollution, waste and sealing failure problems, and is suitable for industrialized batch packaging requirements of inositol powder.

The invention relates to a hyaluronic acid high-yield strain based on metabolic flow optimization as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the corynebacterium glutamicum, sources of key rate-limiting enzymes UDP-glucose dehydrogenase and glutamine-fructose-6-phosphate aminotransferase are screened, and heterologous expression of hyaluronic acid synthase and overexpression of endogenous inositol permease and glucokinase are combined, so that the corynebacterium glutamicum capable of highly producing hyaluronic acid is constructed in a form of optimizing metabolic flux; according to the invention, the hyaluronic acid is used as a substrate, polyhydroxybutyrate synthase clusters are further overexpressed in the substrate, the glucose uptake and utilization efficiency of a host are improved, the metabolic coupling of cofactors is realized, the yield of the hyaluronic acid reaches 45g / L, the production intensity is 1.25 g / L / h, a brand new tool is provided for the production of the hyaluronic acid, and the method has an excellent application prospect.

The present application provides methods for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as a phosphoinositide 3-kinase-delta (PI3Ks) inhibitor, as well as salt forms and intermediates related thereto.

This relates to an inositol derivative and its uses. Specifically, a compound is provided comprising two or more portions of formula (D) connected by a common central linker L2, as shown below.

The application provides a kind of composition for relieving fatigue and its preparation method, belong to relieving fatigue composition technical field.The composition for relieving fatigue of the application includes the following raw materials by mass concentration: Brazilian ginseng-guarana composite water extract 60%-70%, taurine 1%-2%, tea polyphenol 0.2%-0.4%, inositol 0.8%-1.2%, maltitol 1%-1.5%, erythritol 0.5%-1%, stevioside 0.05%-0.1%, citric acid 0.01%-0.02%, malic acid 0.01%-0.02%, vitamin C 0.1%-0.3%, xanthan gum 0.08%-0.12%, and the balance is water.In the composition of the application, Brazilian ginseng-guarana composite water extract provides ecdysterone, caffeine and other core substances, laying the foundation for anti-fatigue;Taurine cooperates to remove lactic acid and reduce serum urea accumulation, inositol regulates energy homeostasis, tea polyphenol and vitamin C strengthen antioxidant protection, and each component plays a synergistic anti-fatigue effect through complementation, and the active ingredients are stable, low-calorie, and excellent in taste.

To provide an immobilized enzyme composition for hexose production or an improved process for hexose production. [Solution] The present invention relates to an immobilized enzyme composition for the preparation of hexoses. Examples of hexoses include tagatose, psicose, fructose, allose, mannose, galactose, altrose, talose, sorbose, gross, idose, and inositol. The present invention also relates to an enzymatic process for preparing hexoses from sugars by contacting starch derivatives with the immobilized enzyme composition of the present invention.

This invention relates to the prevention and / or treatment of protein tyrosine kinase-mediated diseases, particularly phosphatidylinositol 3-kinase (PI3Ks)-mediated diseases. PI3Ks are well known as oncological targets, and several PI3K inhibitors have been developed that inhibit numerous class 1A PI3K isoforms. The development of selective inhibitors of PI3K-α may enable sufficient targeted inhibition while avoiding some of the known toxic drawbacks of pan-PI3K inhibitors. The inventors have discovered that a novel carbamoti-oil-pyrrolidine-carboxamide compound of formula (I) exhibits advantageous PI3K inhibitory activity, particularly with high selectivity for the isoform PI3K-α. In particular, this invention relates to the compound of formula (I), or deuterated or tritiated forms of the compound of formula (I), and pharmaceutically acceptable salts thereof. [Formula 1] The present invention also relates to pharmaceutical compositions containing a compound of formula (I) for use in the treatment and / or prevention of protein tyrosine kinase-mediated diseases, and to a compound of formula (I).

The invention relates to the technical field of microorganisms, in particular to bacillus aryabhattai OF326 and application of the bacillus aryabhattai OF326 to preparation of bio-organic fertilizer and disease resistance, the bacillus aryabhattai OF326 is a probiotic screened by the applicant, research finds that the strain has the functions of IAA production, phosphorus solubilization and nitrogen fixation, growth of rice seedlings can be remarkably promoted, and the yield of the rice seedlings is increased. The method is suitable for secondary fermentation of organic fertilizers with sheep manure and traditional Chinese medicine residues as raw materials, and the viable count of beneficial bacteria is increased. In addition, tests show that the strain OF326 has a remarkable antagonistic effect on ralstonia solanacearum, and a clear antibacterial zone is formed; and by compounding with inositol or trehalose-6-phosphoric acid (T6P), the proliferation of the strain can be further promoted, and the growth rate of the strain is increased. In conclusion, the strain still keeps good growth-promoting and disease-resistant functions under the waterflooding condition, and is suitable for development of biological fertilizers and disease-resistant preparations.

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted GPC3 polypeptide ligand, which has a structural general formula: C-L-P, wherein C is a chelating group; l is a linker; p is a targeted phosphatidylinositol proteoglycan-3 (GPC3) polypeptide pharmacodynamic group; the linker is a covalent linker or a reversible non-covalent linker. The invention has the following technical effects: by introducing the covalent linker or the reversible non-covalent linker, the chemical structure of the targeted GPC3 polypeptide ligand is optimized, the targeting property of the targeted GPC3 polypeptide radiopharmaceutical is improved, and the pharmacokinetic characteristics are improved; the defects that an existing targeted GPC3 polypeptide radiopharmaceutical is low in tumor uptake, short in tumor residence time, poor in pharmacokinetic characteristic and the like are overcome. The invention further discloses a targeted GPC3 polypeptide radiopharmaceutical as well as a preparation method and application of the targeted GPC3 polypeptide radiopharmaceutical.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of inositol fatty acid ester. The method comprises the following steps: (1) mixing acetyl chloride and fatty acid, adding an inositol solution, heating to 80-150 DEG C while stirring under a vacuum condition, and reacting for 20-30 minutes to obtain a mixed solution; and (2) adding ethanol into the mixed solution in the step (1), stirring for 2-3 minutes, standing, layering, separating an upper solution from a lower solution, heating the upper solution at 80-110 DEG C for 5-8 minutes, adding acetyl chloride and an inositol solution, heating to 80-150 DEG C while stirring under a vacuum condition, reacting for 20-30 minutes, and merging with the upper solution to obtain the inositol fatty acid ester. The yield of the prepared inositol fatty acid ester is high.

The invention discloses a nutritional composition for promoting brain development and application thereof, and relates to the technical field of biological medicines. The compound composition is selected from a composition A (melatonin + uridylic acid + inositol), a composition B (melatonin + uridylic acid) and a composition C (uridylic acid + inositol). Experiments prove that the combination B can significantly improve elevated anxiety behaviors and learning and memory ability caused by rhythm disorder, the combination C can significantly improve open field anxiety behaviors caused by rhythm disorder, and the combination A can significantly relieve anxiety behaviors (including elevated and open field) and spatial learning and memory ability disorder caused by rhythm disorder at the same time. The active components in the compound composition disclosed by the invention are remarkable in synergistic effect, high in safety and good in biocompatibility, and can be used for preparing medicines, food additives or feed additives for improving rhythm disorder related brain dysplasia.

The present invention relates generally to the field of myo-inositol-containing compositions for use in the prevention of premature rupture of membranes (PROM) and related disorders and / or conditions. The composition may be a nutritional composition, for example, a maternal nutrition composition. The composition may be specifically designed to provide optimal nutrition to a woman who wishes to become pregnant or to a pregnant woman.

This invention discloses a strain of Rhodotorula glutinis I7Y2 that promotes cell proliferation in a serum-free environment and its applications. Rhodotorula glutinis ( Rhodotorula mucilaginosa The yeast strain I7Y2 was deposited at the Guangdong Provincial Microbial Culture Collection Center (GDMCC) on March 13, 2026, with accession number GDMCC No: 67951. This invention has a good effect on promoting Vero cell proliferation, specifically manifested in: (1) the yeast involved in this invention can produce various active substances such as amino acids, polypeptides, sanshool, and inositol to meet the nutritional needs of cell growth; (2) it can effectively improve the viability and density of Vero cells in the basal culture medium; (3) it can effectively improve the proliferation rate and migration rate of Vero cells in the basal culture medium; and (4) it can effectively reduce the apoptosis rate of Vero cells and the expression of apoptosis-related genes in the basal culture medium. Therefore, Rhodotorula glutinis I7Y2 has great application potential in promoting cell proliferation, especially in serum-free culture products.

This invention discloses a method for quantitatively detecting muscle inositol in blood. It employs an electrochemical method and specifically includes the following steps: a) preparation of a series of standard working solutions; b) preparation of a blank sample solution; c) plotting a standard curve using differential pulse voltammetry (DPV) with the blank sample solution and the series of standard working solutions; d) preparation of the test sample solution; e) determination of the muscle inositol content in the test sample. Experiments have demonstrated that the method of this invention yields accurate and reliable results and can be used for clinical blood testing.

The invention belongs to the technical field of genetic engineering, and discloses an inositol-3-phosphate synthase mutant and a preparation method of inositol. Compared with an amino acid fragment as shown in SEQ ID NO: 1, the inositol-3-phosphate synthase mutant provided by the invention comprises substitution mutation at one or more sites of the 132 site, the 181 site, the 211 site and the 324 site, and the introduction of the substitution mutation can realize structural optimization of a catalytic active center in the inositol-3-phosphate synthase; the method has the advantages that substrate combination, oxidation reaction and condensation reaction are benefited, so that the obtained inositol-3-phosphate synthase mutant is endowed with excellent activity of catalyzing glucose-6-phosphate to generate inositol-3-phosphate and can be well applied to in-vitro enzyme cascade reaction for synthesis of inositol, high-yield and high-efficiency production of inositol is realized, and the method is suitable for industrial production. And the method has an excellent practical application prospect.

The invention discloses a preparation method of inositol nicotinate tablets, and belongs to the technical field of pharmaceutical preparations. By optimizing the existing process and coating components, stable dissolution of drugs is realized, and the method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase and a water phase, performing spray drying to obtain drug milk powder, coating the drug milk powder with modified chitosan, and directly tabletting the coated drug milk powder and auxiliary materials. The preparation method comprises the following steps: uniformly dispersing inositol nicotinate in mixed oil to promote the inositol nicotinate to maintain the uniformity of the drug content in the subsequent process, and adsorbing solid particles on the surfaces of drug-containing oil drops through an emulsification technology to protect the drug components; coating components are reasonably designed, so that fixed-point release of the medicine is realized, the medicine is endowed with anti-pressure ability, and the medicine can be directly tableted; and the coated medicine particles are mixed with auxiliary materials and then are directly tableted, so that the process is simplified, and the coating structure of the medicine particles is protected at the same time. The preparation method can prepare the inositol nicotinate tablet with stable drug dissolution, and the inositol nicotinate tablet is good in taste and small in stimulation to gastric mucosa.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The invention relates to the technical field of plant cultivation, in particular to a eucommia ulmoides tissue culture seedling rooting induction and large-scale rapid propagation cultivation method which comprises the following raw materials: a modified basic culture medium, modified naphthylacetic acid, modified sucrose, inositol, activated carbon and agar. According to the invention, the modified basic culture medium converts a traditional nutrient medium into an active substrate with biological stimulation and signal initiation functions; the modified naphthylacetic acid realizes stable slow release and biological activation of the auxin, and provides a lasting and mild induction signal; the modified sucrose has a multifunctional carbon source for stress resistance protection, mineral supply and physical support; under the synergism of the three, a continuous action period of starting, inducing and protecting is formed, the structure and the air permeability of a rhizosphere microenvironment are jointly optimized in space, endogenous / exogenous signals are integrated in a physiological level, a key enzyme system is activated, and the cell stress resistance is enhanced, so that the rooting rate, the root system quality and the transplanting survival rate of eucommia ulmoides tissue culture seedlings are synergistically and remarkably improved.

The present technology generally relates to peptides that bind to phosphatidylinositol proteoglycan 3 (GPC3), to peptides that bind to the GPC3, and to compositions comprising such peptides.

This invention discloses a leak-proof, highly elastic phase change gel ice pack material and its preparation method. The ice pack material is based on a synergistically modified polymer matrix composed of polyvinyl alcohol and sodium alginate. A stable physical cross-linked structure is constructed through the synergistic effect of calcium chloride and sorbitol. Inositol is introduced as an organic small molecule structure regulator, ensuring that the phase change cold storage medium, polyol humectant, and inorganic stabilizing agent are uniformly and stably dispersed in the gel system. The phase change gel ice pack material obtained by the above preparation method maintains good structural integrity and elastic recovery performance under pressure and repeated freeze-thaw conditions, effectively reducing the migration and leakage risk of the phase change cold storage medium. It features stable phase change performance, significant leak-proof effect, and high safety in use, making it suitable for cold chain transportation, medical cold compresses, and daily cold storage applications.

The present technology relates to the field of cancer treatment. In particular, the present technology relates to polypeptides targeting phosphatidylinositolprotein-3 (GPC3) and T cell receptor (TCR) for use in the treatment of phosphatidylinositolprotein-3 positive (GPC3 +) solid tumors, such as hepatocellular carcinoma (HCC) or non-small cell lung cancer (NSCLC). In addition, the technology relates to the dosage of said polypeptide when used as therapy.

The invention belongs to the technical field of oil exploitation, and particularly relates to a composite blocking remover and a preparation method and application thereof. The composite blocking remover comprises the following components in percentage by weight, comprising the following components in percentage by weight: 5 to 8 percent of hydrochloric acid, 1 to 3 percent of fluoboric acid, 0.5 to 2 percent of acetic acid, 0.5 to 1 percent of dodecyl trimethyl ammonium chloride, 0.1 to 0.3 percent of potassium chloride, 0.3 to 0.8 percent of sodium erythorbate, 0.2 to 0.5 percent of tetrasodium glutamate diacetate, 1 to 2 percent of ethylenediamine tetraacetic acid, 0.1 to 0.2 percent of inositol hexaphosphate, 0.1 to 0.2 percent of cocoanut fatty acid diethanolamide, 0.3 to 0.5 percent of sodium dodecyl benzene sulfonate, 0.3 to 0.5 percent of dimethyl diallyl ammonium chloride, 0.1 to 0.2 percent of ethylene glycol monobutyl ether and the balance of water. The composite blocking remover provided by the invention does not generate the problem of secondary precipitation, slows down the reaction speed of acid rocks, effectively pushes a blocking removal measure solution into the deep part of a stratum, enlarges the blocking removal radius, realizes deep treatment of the stratum, improves the acidification effect, and prolongs the effective action time of acidification.

This invention discloses an enzyme preparation and a method for preparing squalene, belonging to the field of genetic engineering technology. The enzyme preparation includes inositol-2-dehydrogenase and squalene dehydrogenase. The amino acid sequence of inositol-2-dehydrogenase is shown in SEQ ID NO. 6, and the amino acid sequence of squalene dehydrogenase is shown in SEQ ID NO. 8 or SEQ ID NO. 10. This invention mutates wild-type inositol-2-dehydrogenase and wild-type squalene dehydrogenase to obtain specific amino acid sequence mutants: inositol-2-dehydrogenase mutant D270P, squalene dehydrogenase mutant H89L, and squalene dehydrogenase mutant H89L / A294R. These mutants exhibit higher enzyme activity, effectively improving the yield and conversion efficiency of squalene during preparation.